Company profile
Heron Therapeutics, Inc.
NASDAQ: HRTX · Healthcare · Biotechnology
PublicHQ Cary, CACIK 0000818033Reports USD
#307 of 1,418 Healthcare companies by revenue52nd-percentile growth
EA Score
58CFH 51DQ 60GM 66SS 74
v0.1 · 65/100 weight · provisional
↑ listing tenure, growth stability · ↓ return on equity, balance-sheet leverage
Methodology →Revenue TTM
$150.7M
Rev growth YoY (TTM)
+1.5%
Net income (FY)
-$20.2M
Employees
128
as of 2026-08-19
Market cap
$57.0M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$154.9M$154.9M2025
Net income-$20.2M-$20.2M2025
Operating income-$2.5M-$2.5M2025
Total assets$255.9M$255.9M2025
Liabilities$241.5M$241.5M2025
Equity$14.3M$14.3M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
C I N V A N T I68%
Z Y N R E L E F27%
S U S T O L6%
By geography
Not disclosed.
The read
What is Heron Therapeutics, Inc.’s revenue?
Heron Therapeutics, Inc. booked $154.9M in FY2025 revenue, growing 7.4% year over year — about the middle of the pack among Healthcare companies we track, at a -13.0% net margin.
Peers · Healthcare
Pacific Biosciences of California, Inc.55CMariMed Inc.66BLiquidia Corporation58CAirSculpt Technologies, Inc.58CMacroGenics, Inc.54DNeuronetics, Inc.59CKey facts
CEOCraig Alexander Collard
SectorHealthcare
IndustryBiotechnology
HeadquartersCary, CA
ExchangeNASDAQ: HRTX
Employees128
IPO date1987-08-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.